{
    "medicine_id": "b2c3d34f5082a407cede71380e46bc3861454eb4",
    "platform_id": "DB08871",
    "metadata": {
        "name": "Halaven 0 44 mg ml Injection solution",
        "composition": "0 44 mg ml Eribulin",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer",
            "contraindications": {
                "disease": "Peripheral neuropathy was the most common toxicity leading to discontinuation of eribulin 5 percent Richard Pazdur M D director of the FDA s Division of Oncology Drug Products Single doses of 0 75 mg kg were lethal to rats and two doses of 0 075 mg kg were lethal to dogs The no observed adverse effect level NOAEL in rats and dogs were 0 015 and 0 0045 mg kg day respectively",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Linear",
                "excipients": "NA",
                "incompatibilities": [
                    {
                        "drugbank-id": "DB06643",
                        "description": "The risk or severity of adverse effects can be increased when Denosumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00005",
                        "description": "The risk or severity of adverse effects can be increased when Etanercept is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00008",
                        "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa 2a is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00011",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa n1 is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00018",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa n3 is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00022",
                        "description": "The risk or severity of adverse effects can be increased when Peginterferon alfa 2b is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00026",
                        "description": "The risk or severity of adverse effects can be increased when Anakinra is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00033",
                        "description": "The risk or severity of adverse effects can be increased when Interferon gamma 1b is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00034",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa 2a Recombinant is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00041",
                        "description": "The risk or severity of adverse effects can be increased when Aldesleukin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00051",
                        "description": "The risk or severity of adverse effects can be increased when Adalimumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00056",
                        "description": "The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00059",
                        "description": "The risk or severity of adverse effects can be increased when Pegaspargase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00065",
                        "description": "The risk or severity of adverse effects can be increased when Infliximab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00068",
                        "description": "The risk or severity of adverse effects can be increased when Interferon beta 1b is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00069",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfacon 1 is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00073",
                        "description": "The risk or severity of adverse effects can be increased when Rituximab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00074",
                        "description": "The risk or severity of adverse effects can be increased when Basiliximab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00075",
                        "description": "The risk or severity of adverse effects can be increased when Muromonab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00078",
                        "description": "The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00081",
                        "description": "The risk or severity of adverse effects can be increased when Tositumomab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00087",
                        "description": "The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00092",
                        "description": "The risk or severity of adverse effects can be increased when Alefacept is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00095",
                        "description": "The risk or severity of adverse effects can be increased when Efalizumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00098",
                        "description": "The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin rabbit is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00105",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa 2b is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00111",
                        "description": "The risk or severity of adverse effects can be increased when Daclizumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00112",
                        "description": "The risk or severity of adverse effects can be increased when Bevacizumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00120",
                        "description": "The risk or severity of adverse effects can be increased when Phenylalanine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00180",
                        "description": "The risk or severity of adverse effects can be increased when Flunisolide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00188",
                        "description": "The risk or severity of adverse effects can be increased when Bortezomib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00242",
                        "description": "The risk or severity of adverse effects can be increased when Cladribine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00262",
                        "description": "The risk or severity of adverse effects can be increased when Carmustine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00276",
                        "description": "The risk or severity of adverse effects can be increased when Amsacrine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00290",
                        "description": "The risk or severity of adverse effects can be increased when Bleomycin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00291",
                        "description": "The risk or severity of adverse effects can be increased when Chlorambucil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00293",
                        "description": "The risk or severity of adverse effects can be increased when Raltitrexed is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00305",
                        "description": "The risk or severity of adverse effects can be increased when Mitomycin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00307",
                        "description": "The risk or severity of adverse effects can be increased when Bexarotene is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00309",
                        "description": "The risk or severity of adverse effects can be increased when Vindesine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00322",
                        "description": "The risk or severity of adverse effects can be increased when Floxuridine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00328",
                        "description": "The risk or severity of adverse effects can be increased when Indomethacin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00352",
                        "description": "The risk or severity of adverse effects can be increased when Tioguanine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00361",
                        "description": "The risk or severity of adverse effects can be increased when Vinorelbine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00380",
                        "description": "The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00394",
                        "description": "The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00398",
                        "description": "The risk or severity of adverse effects can be increased when Sorafenib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00428",
                        "description": "The risk or severity of adverse effects can be increased when Streptozocin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00432",
                        "description": "The risk or severity of adverse effects can be increased when Trifluridine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00441",
                        "description": "The risk or severity of adverse effects can be increased when Gemcitabine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00443",
                        "description": "The risk or severity of adverse effects can be increased when Betamethasone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00444",
                        "description": "The risk or severity of adverse effects can be increased when Teniposide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00446",
                        "description": "The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00480",
                        "description": "The risk or severity of adverse effects can be increased when Lenalidomide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00488",
                        "description": "The risk or severity of adverse effects can be increased when Altretamine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00495",
                        "description": "The risk or severity of adverse effects can be increased when Zidovudine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00515",
                        "description": "The risk or severity of adverse effects can be increased when Cisplatin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00526",
                        "description": "The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00531",
                        "description": "The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00541",
                        "description": "The risk or severity of adverse effects can be increased when Vincristine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00544",
                        "description": "The risk or severity of adverse effects can be increased when Fluorouracil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00550",
                        "description": "The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00552",
                        "description": "The risk or severity of adverse effects can be increased when Pentostatin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00563",
                        "description": "The risk or severity of adverse effects can be increased when Methotrexate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00564",
                        "description": "The risk or severity of adverse effects can be increased when Carbamazepine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00570",
                        "description": "The risk or severity of adverse effects can be increased when Vinblastine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00588",
                        "description": "The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00591",
                        "description": "The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00601",
                        "description": "The risk or severity of adverse effects can be increased when Linezolid is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00619",
                        "description": "The risk or severity of adverse effects can be increased when Imatinib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00620",
                        "description": "The risk or severity of adverse effects can be increased when Triamcinolone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00631",
                        "description": "The risk or severity of adverse effects can be increased when Clofarabine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00635",
                        "description": "The risk or severity of adverse effects can be increased when Prednisone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00642",
                        "description": "The risk or severity of adverse effects can be increased when Pemetrexed is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00687",
                        "description": "The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00688",
                        "description": "The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00694",
                        "description": "The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00755",
                        "description": "The risk or severity of adverse effects can be increased when Tretinoin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00762",
                        "description": "The risk or severity of adverse effects can be increased when Irinotecan is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00763",
                        "description": "The risk or severity of adverse effects can be increased when Methimazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00773",
                        "description": "The risk or severity of adverse effects can be increased when Etoposide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00795",
                        "description": "The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00851",
                        "description": "The risk or severity of adverse effects can be increased when Dacarbazine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00853",
                        "description": "The risk or severity of adverse effects can be increased when Temozolomide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00859",
                        "description": "The risk or severity of adverse effects can be increased when Penicillamine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00860",
                        "description": "The risk or severity of adverse effects can be increased when Prednisolone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00877",
                        "description": "The risk or severity of adverse effects can be increased when Sirolimus is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00888",
                        "description": "The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00928",
                        "description": "The risk or severity of adverse effects can be increased when Azacitidine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00958",
                        "description": "The risk or severity of adverse effects can be increased when Carboplatin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00959",
                        "description": "The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00970",
                        "description": "The risk or severity of adverse effects can be increased when Dactinomycin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00987",
                        "description": "The risk or severity of adverse effects can be increased when Cytarabine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00993",
                        "description": "The risk or severity of adverse effects can be increased when Azathioprine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00997",
                        "description": "The risk or severity of adverse effects can be increased when Doxorubicin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01005",
                        "description": "The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01008",
                        "description": "The risk or severity of adverse effects can be increased when Busulfan is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01024",
                        "description": "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01030",
                        "description": "The risk or severity of adverse effects can be increased when Topotecan is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01033",
                        "description": "The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01041",
                        "description": "The risk or severity of adverse effects can be increased when Thalidomide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01042",
                        "description": "The risk or severity of adverse effects can be increased when Melphalan is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01073",
                        "description": "The risk or severity of adverse effects can be increased when Fludarabine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01099",
                        "description": "The risk or severity of adverse effects can be increased when Flucytosine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01101",
                        "description": "The risk or severity of adverse effects can be increased when Capecitabine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01108",
                        "description": "The risk or severity of adverse effects can be increased when Trilostane is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01168",
                        "description": "The risk or severity of adverse effects can be increased when Procarbazine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01169",
                        "description": "The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01177",
                        "description": "The risk or severity of adverse effects can be increased when Idarubicin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01181",
                        "description": "The risk or severity of adverse effects can be increased when Ifosfamide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01196",
                        "description": "The risk or severity of adverse effects can be increased when Estramustine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01204",
                        "description": "The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01206",
                        "description": "The risk or severity of adverse effects can be increased when Lomustine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01222",
                        "description": "The risk or severity of adverse effects can be increased when Budesonide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01229",
                        "description": "The risk or severity of adverse effects can be increased when Paclitaxel is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01234",
                        "description": "The risk or severity of adverse effects can be increased when Dexamethasone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01248",
                        "description": "The risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01254",
                        "description": "The risk or severity of adverse effects can be increased when Dasatinib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01257",
                        "description": "The risk or severity of adverse effects can be increased when Eculizumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01262",
                        "description": "The risk or severity of adverse effects can be increased when Decitabine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01268",
                        "description": "The risk or severity of adverse effects can be increased when Sunitinib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01280",
                        "description": "The risk or severity of adverse effects can be increased when Nelarabine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01281",
                        "description": "The risk or severity of adverse effects can be increased when Abatacept is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01285",
                        "description": "The risk or severity of adverse effects can be increased when Corticotropin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01380",
                        "description": "The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01384",
                        "description": "The risk or severity of adverse effects can be increased when Paramethasone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01394",
                        "description": "The risk or severity of adverse effects can be increased when Colchicine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01410",
                        "description": "The risk or severity of adverse effects can be increased when Ciclesonide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01423",
                        "description": "The risk or severity of adverse effects can be increased when Stepronin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01590",
                        "description": "The risk or severity of adverse effects can be increased when Everolimus is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01611",
                        "description": "The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01816",
                        "description": "The risk or severity of adverse effects can be increased when Castanospermine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB02546",
                        "description": "The risk or severity of adverse effects can be increased when Vorinostat is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB02806",
                        "description": "The risk or severity of adverse effects can be increased when 2 Methoxyethanol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB03523",
                        "description": "The risk or severity of adverse effects can be increased when Brequinar is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04572",
                        "description": "The risk or severity of adverse effects can be increased when Thiotepa is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04630",
                        "description": "The risk or severity of adverse effects can be increased when Aldosterone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04845",
                        "description": "The risk or severity of adverse effects can be increased when Ixabepilone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04868",
                        "description": "The risk or severity of adverse effects can be increased when Nilotinib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04951",
                        "description": "The risk or severity of adverse effects can be increased when Pirfenidone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04956",
                        "description": "The risk or severity of adverse effects can be increased when Afelimomab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05015",
                        "description": "The risk or severity of adverse effects can be increased when Belinostat is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05109",
                        "description": "The risk or severity of adverse effects can be increased when Trabectedin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05258",
                        "description": "The risk or severity of adverse effects can be increased when Interferon alfa is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05259",
                        "description": "The risk or severity of adverse effects can be increased when Glatiramer is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05260",
                        "description": "The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05459",
                        "description": "The risk or severity of adverse effects can be increased when Briakinumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05472",
                        "description": "The risk or severity of adverse effects can be increased when Human interferon omega 1 is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05676",
                        "description": "The risk or severity of adverse effects can be increased when Apremilast is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05773",
                        "description": "The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06168",
                        "description": "The risk or severity of adverse effects can be increased when Canakinumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06273",
                        "description": "The risk or severity of adverse effects can be increased when Tocilizumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06287",
                        "description": "The risk or severity of adverse effects can be increased when Temsirolimus is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06372",
                        "description": "The risk or severity of adverse effects can be increased when Rilonacept is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06589",
                        "description": "The risk or severity of adverse effects can be increased when Pazopanib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06603",
                        "description": "The risk or severity of adverse effects can be increased when Panobinostat is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06612",
                        "description": "The risk or severity of adverse effects can be increased when Mepolizumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06616",
                        "description": "The risk or severity of adverse effects can be increased when Bosutinib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06662",
                        "description": "The risk or severity of adverse effects can be increased when Abetimus is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06674",
                        "description": "The risk or severity of adverse effects can be increased when Golimumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06681",
                        "description": "The risk or severity of adverse effects can be increased when Belatacept is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06769",
                        "description": "The risk or severity of adverse effects can be increased when Bendamustine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06772",
                        "description": "The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06813",
                        "description": "The risk or severity of adverse effects can be increased when Pralatrexate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08059",
                        "description": "The risk or severity of adverse effects can be increased when Wortmannin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08870",
                        "description": "The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08877",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Ruxolitinib"
                    },
                    {
                        "drugbank-id": "DB08879",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Belimumab"
                    },
                    {
                        "drugbank-id": "DB08880",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Teriflunomide"
                    },
                    {
                        "drugbank-id": "DB08889",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Carfilzomib"
                    },
                    {
                        "drugbank-id": "DB08901",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Ponatinib"
                    },
                    {
                        "drugbank-id": "DB08904",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Certolizumab pegol"
                    },
                    {
                        "drugbank-id": "DB08906",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Fluticasone furoate"
                    },
                    {
                        "drugbank-id": "DB08908",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Dimethyl fumarate"
                    },
                    {
                        "drugbank-id": "DB08910",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Pomalidomide"
                    },
                    {
                        "drugbank-id": "DB08935",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Obinutuzumab"
                    },
                    {
                        "drugbank-id": "DB08970",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Fluprednidene"
                    },
                    {
                        "drugbank-id": "DB09029",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Secukinumab"
                    },
                    {
                        "drugbank-id": "DB09033",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Vedolizumab"
                    },
                    {
                        "drugbank-id": "DB09036",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Siltuximab"
                    },
                    {
                        "drugbank-id": "DB09052",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Blinatumomab"
                    },
                    {
                        "drugbank-id": "DB09053",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Ibrutinib"
                    },
                    {
                        "drugbank-id": "DB09054",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Idelalisib"
                    },
                    {
                        "drugbank-id": "DB09073",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Palbociclib"
                    },
                    {
                        "drugbank-id": "DB09074",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Olaparib"
                    },
                    {
                        "drugbank-id": "DB09077",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Dinutuximab"
                    },
                    {
                        "drugbank-id": "DB09082",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Vilanterol"
                    },
                    {
                        "drugbank-id": "DB09091",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Tixocortol"
                    },
                    {
                        "drugbank-id": "DB09122",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Peginterferon beta 1a"
                    },
                    {
                        "drugbank-id": "DB09312",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Antilymphocyte immunoglobulin horse"
                    },
                    {
                        "drugbank-id": "DB09378",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Fluprednisolone"
                    },
                    {
                        "drugbank-id": "DB09383",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Meprednisone"
                    },
                    {
                        "drugbank-id": "DB11466",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Tepoxalin"
                    },
                    {
                        "drugbank-id": "DB11487",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Dexamethasone isonicotinate"
                    },
                    {
                        "drugbank-id": "DB11529",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Melengestrol"
                    },
                    {
                        "drugbank-id": "DB11569",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Ixekizumab"
                    },
                    {
                        "drugbank-id": "DB11580",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Ravulizumab"
                    },
                    {
                        "drugbank-id": "DB11616",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Pirarubicin"
                    },
                    {
                        "drugbank-id": "DB11693",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Voclosporin"
                    },
                    {
                        "drugbank-id": "DB11708",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Peficitinib"
                    },
                    {
                        "drugbank-id": "DB11767",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Sarilumab"
                    },
                    {
                        "drugbank-id": "DB11776",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Brodalumab"
                    },
                    {
                        "drugbank-id": "DB11803",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Sirukumab"
                    },
                    {
                        "drugbank-id": "DB11817",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Baricitinib"
                    },
                    {
                        "drugbank-id": "DB11834",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Guselkumab"
                    },
                    {
                        "drugbank-id": "DB11921",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Deflazacort"
                    },
                    {
                        "drugbank-id": "DB12025",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Triptolide"
                    },
                    {
                        "drugbank-id": "DB12371",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Siponimod"
                    },
                    {
                        "drugbank-id": "DB12612",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Ozanimod"
                    },
                    {
                        "drugbank-id": "DB12617",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Mizoribine"
                    },
                    {
                        "drugbank-id": "DB12692",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Gusperimus"
                    },
                    {
                        "drugbank-id": "DB12814",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Cepeginterferon alfa 2B"
                    },
                    {
                        "drugbank-id": "DB12902",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Trofosfamide"
                    },
                    {
                        "drugbank-id": "DB12947",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Doxifluridine"
                    },
                    {
                        "drugbank-id": "DB12991",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Deoxyspergualin"
                    },
                    {
                        "drugbank-id": "DB12996",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Acteoside"
                    },
                    {
                        "drugbank-id": "DB13003",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Cortivazol"
                    },
                    {
                        "drugbank-id": "DB13014",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Hypericin"
                    },
                    {
                        "drugbank-id": "DB13068",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with 9 N methyl L isoleucine cyclosporin A"
                    },
                    {
                        "drugbank-id": "DB13208",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Prednylidene"
                    },
                    {
                        "drugbank-id": "DB13223",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Fluocortin"
                    },
                    {
                        "drugbank-id": "DB13241",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Begelomab"
                    },
                    {
                        "drugbank-id": "DB13491",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Fluperolone"
                    },
                    {
                        "drugbank-id": "DB13843",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Cloprednol"
                    },
                    {
                        "drugbank-id": "DB13856",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Fluclorolone"
                    },
                    {
                        "drugbank-id": "DB13867",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Fluticasone"
                    },
                    {
                        "drugbank-id": "DB14066",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Tetrandrine"
                    },
                    {
                        "drugbank-id": "DB14219",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Monomethyl fumarate"
                    },
                    {
                        "drugbank-id": "DB14512",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Mometasone furoate"
                    },
                    {
                        "drugbank-id": "DB14539",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Hydrocortisone acetate"
                    },
                    {
                        "drugbank-id": "DB14545",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Hydrocortisone succinate"
                    },
                    {
                        "drugbank-id": "DB14724",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Emapalumab"
                    },
                    {
                        "drugbank-id": "DB14762",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Risankizumab"
                    },
                    {
                        "drugbank-id": "DB14919",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Rozanolixizumab"
                    },
                    {
                        "drugbank-id": "DB15253",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Bleselumab"
                    },
                    {
                        "drugbank-id": "DB00445",
                        "description": "The risk or severity of adverse effects can be increased when Epirubicin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01013",
                        "description": "The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01047",
                        "description": "The risk or severity of adverse effects can be increased when Fluocinonide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14540",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Hydrocortisone butyrate"
                    },
                    {
                        "drugbank-id": "DB00547",
                        "description": "The risk or severity of adverse effects can be increased when Desoximetasone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00764",
                        "description": "The risk or severity of adverse effects can be increased when Mometasone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08971",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Fluocortolone"
                    },
                    {
                        "drugbank-id": "DB11750",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Clobetasol"
                    },
                    {
                        "drugbank-id": "DB00324",
                        "description": "The risk or severity of adverse effects can be increased when Fluorometholone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09095",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Difluocortolone"
                    },
                    {
                        "drugbank-id": "DB00108",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Natalizumab"
                    },
                    {
                        "drugbank-id": "DB00337",
                        "description": "The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01656",
                        "description": "Roflumilast may increase the immunosuppressive activities of Eribulin"
                    },
                    {
                        "drugbank-id": "DB06688",
                        "description": "The therapeutic efficacy of Sipuleucel T can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00363",
                        "description": "The risk or severity of neutropenia can be increased when Eribulin is combined with Clozapine"
                    },
                    {
                        "drugbank-id": "DB00012",
                        "description": "The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00016",
                        "description": "The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08894",
                        "description": "The risk or severity of Thrombosis can be increased when Peginesatide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09107",
                        "description": "The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol epoetin beta is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01015",
                        "description": "The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01097",
                        "description": "The risk or severity of adverse effects can be increased when Eribulin is combined with Leflunomide"
                    },
                    {
                        "drugbank-id": "DB08895",
                        "description": "Eribulin may increase the immunosuppressive activities of Tofacitinib"
                    },
                    {
                        "drugbank-id": "DB00072",
                        "description": "Trastuzumab may increase the neutropenic activities of Eribulin"
                    },
                    {
                        "drugbank-id": "DB08868",
                        "description": "Eribulin may increase the immunosuppressive activities of Fingolimod"
                    },
                    {
                        "drugbank-id": "DB00864",
                        "description": "Tacrolimus may increase the immunosuppressive activities of Eribulin"
                    },
                    {
                        "drugbank-id": "DB00007",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Leuprolide"
                    },
                    {
                        "drugbank-id": "DB00014",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Goserelin"
                    },
                    {
                        "drugbank-id": "DB00195",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Betaxolol"
                    },
                    {
                        "drugbank-id": "DB00199",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Erythromycin"
                    },
                    {
                        "drugbank-id": "DB00207",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Azithromycin"
                    },
                    {
                        "drugbank-id": "DB00218",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Moxifloxacin"
                    },
                    {
                        "drugbank-id": "DB00243",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ranolazine"
                    },
                    {
                        "drugbank-id": "DB00263",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sulfisoxazole"
                    },
                    {
                        "drugbank-id": "DB00321",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Amitriptyline"
                    },
                    {
                        "drugbank-id": "DB00333",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Methadone"
                    },
                    {
                        "drugbank-id": "DB00343",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Diltiazem"
                    },
                    {
                        "drugbank-id": "DB00391",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sulpiride"
                    },
                    {
                        "drugbank-id": "DB00393",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Nimodipine"
                    },
                    {
                        "drugbank-id": "DB00420",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Promazine"
                    },
                    {
                        "drugbank-id": "DB00433",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Prochlorperazine"
                    },
                    {
                        "drugbank-id": "DB00450",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Droperidol"
                    },
                    {
                        "drugbank-id": "DB00458",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Imipramine"
                    },
                    {
                        "drugbank-id": "DB00477",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Chlorpromazine"
                    },
                    {
                        "drugbank-id": "DB00537",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ciprofloxacin"
                    },
                    {
                        "drugbank-id": "DB00556",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Perflutren"
                    },
                    {
                        "drugbank-id": "DB00568",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Cinnarizine"
                    },
                    {
                        "drugbank-id": "DB00571",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Propranolol"
                    },
                    {
                        "drugbank-id": "DB00572",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Atropine"
                    },
                    {
                        "drugbank-id": "DB00608",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Chloroquine"
                    },
                    {
                        "drugbank-id": "DB00625",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Efavirenz"
                    },
                    {
                        "drugbank-id": "DB00640",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Adenosine"
                    },
                    {
                        "drugbank-id": "DB00738",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pentamidine"
                    },
                    {
                        "drugbank-id": "DB00743",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Gadobenic acid"
                    },
                    {
                        "drugbank-id": "DB00748",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Carbinoxamine"
                    },
                    {
                        "drugbank-id": "DB00757",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dolasetron"
                    },
                    {
                        "drugbank-id": "DB00778",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Roxithromycin"
                    },
                    {
                        "drugbank-id": "DB00779",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Nalidixic acid"
                    },
                    {
                        "drugbank-id": "DB00827",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Cinoxacin"
                    },
                    {
                        "drugbank-id": "DB00836",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Loperamide"
                    },
                    {
                        "drugbank-id": "DB00889",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Granisetron"
                    },
                    {
                        "drugbank-id": "DB00904",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ondansetron"
                    },
                    {
                        "drugbank-id": "DB00922",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Levosimendan"
                    },
                    {
                        "drugbank-id": "DB00933",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mesoridazine"
                    },
                    {
                        "drugbank-id": "DB00967",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Desloratadine"
                    },
                    {
                        "drugbank-id": "DB00976",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Telithromycin"
                    },
                    {
                        "drugbank-id": "DB00978",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lomefloxacin"
                    },
                    {
                        "drugbank-id": "DB00985",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dimenhydrinate"
                    },
                    {
                        "drugbank-id": "DB01087",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Primaquine"
                    },
                    {
                        "drugbank-id": "DB01113",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Papaverine"
                    },
                    {
                        "drugbank-id": "DB01114",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Chlorpheniramine"
                    },
                    {
                        "drugbank-id": "DB01115",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Nifedipine"
                    },
                    {
                        "drugbank-id": "DB01137",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Levofloxacin"
                    },
                    {
                        "drugbank-id": "DB01155",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Gemifloxacin"
                    },
                    {
                        "drugbank-id": "DB01165",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ofloxacin"
                    },
                    {
                        "drugbank-id": "DB01182",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Propafenone"
                    },
                    {
                        "drugbank-id": "DB01193",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Acebutolol"
                    },
                    {
                        "drugbank-id": "DB01195",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Flecainide"
                    },
                    {
                        "drugbank-id": "DB01211",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Clarithromycin"
                    },
                    {
                        "drugbank-id": "DB01227",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Levacetylmethadol"
                    },
                    {
                        "drugbank-id": "DB01232",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Saquinavir"
                    },
                    {
                        "drugbank-id": "DB01242",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Clomipramine"
                    },
                    {
                        "drugbank-id": "DB01388",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mibefradil"
                    },
                    {
                        "drugbank-id": "DB01580",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Oxprenolol"
                    },
                    {
                        "drugbank-id": "DB01599",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Probucol"
                    },
                    {
                        "drugbank-id": "DB01615",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Aceprometazine"
                    },
                    {
                        "drugbank-id": "DB02638",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Terlipressin"
                    },
                    {
                        "drugbank-id": "DB04825",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Prenylamine"
                    },
                    {
                        "drugbank-id": "DB04842",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Fluspirilene"
                    },
                    {
                        "drugbank-id": "DB04948",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lofexidine"
                    },
                    {
                        "drugbank-id": "DB04957",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Azimilide"
                    },
                    {
                        "drugbank-id": "DB05223",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pracinostat"
                    },
                    {
                        "drugbank-id": "DB05488",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Technetium Tc 99m ciprofloxacin"
                    },
                    {
                        "drugbank-id": "DB06160",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Garenoxacin"
                    },
                    {
                        "drugbank-id": "DB06200",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Tedisamil"
                    },
                    {
                        "drugbank-id": "DB06334",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Tucidinostat"
                    },
                    {
                        "drugbank-id": "DB06402",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Telavancin"
                    },
                    {
                        "drugbank-id": "DB06600",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Nemonoxacin"
                    },
                    {
                        "drugbank-id": "DB06712",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Nilvadipine"
                    },
                    {
                        "drugbank-id": "DB08799",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Antazoline"
                    },
                    {
                        "drugbank-id": "DB08865",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Crizotinib"
                    },
                    {
                        "drugbank-id": "DB08903",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Bedaquiline"
                    },
                    {
                        "drugbank-id": "DB08952",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Indenolol"
                    },
                    {
                        "drugbank-id": "DB08980",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Fendiline"
                    },
                    {
                        "drugbank-id": "DB08992",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Eperisone"
                    },
                    {
                        "drugbank-id": "DB09016",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Butriptyline"
                    },
                    {
                        "drugbank-id": "DB09063",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ceritinib"
                    },
                    {
                        "drugbank-id": "DB09078",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lenvatinib"
                    },
                    {
                        "drugbank-id": "DB09224",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Melperone"
                    },
                    {
                        "drugbank-id": "DB09231",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Benidipine"
                    },
                    {
                        "drugbank-id": "DB09555",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dexchlorpheniramine maleate"
                    },
                    {
                        "drugbank-id": "DB11640",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Amifampridine"
                    },
                    {
                        "drugbank-id": "DB11830",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mocetinostat"
                    },
                    {
                        "drugbank-id": "DB11841",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Entinostat"
                    },
                    {
                        "drugbank-id": "DB12141",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Gilteritinib"
                    },
                    {
                        "drugbank-id": "DB12174",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with CUDC 101"
                    },
                    {
                        "drugbank-id": "DB12286",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Simendan"
                    },
                    {
                        "drugbank-id": "DB12376",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ricolinostat"
                    },
                    {
                        "drugbank-id": "DB12523",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mizolastine"
                    },
                    {
                        "drugbank-id": "DB12565",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Abexinostat"
                    },
                    {
                        "drugbank-id": "DB12877",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Oxatomide"
                    },
                    {
                        "drugbank-id": "DB13261",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sitafloxacin"
                    },
                    {
                        "drugbank-id": "DB13273",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sultopride"
                    },
                    {
                        "drugbank-id": "DB13500",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Otilonium"
                    },
                    {
                        "drugbank-id": "DB13546",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Nizofenone"
                    },
                    {
                        "drugbank-id": "DB13652",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Bunaftine"
                    },
                    {
                        "drugbank-id": "DB13653",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lorcainide"
                    },
                    {
                        "drugbank-id": "DB13679",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dexchlorpheniramine"
                    },
                    {
                        "drugbank-id": "DB13791",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Penfluridol"
                    },
                    {
                        "drugbank-id": "DB14063",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dexverapamil"
                    },
                    {
                        "drugbank-id": "DB14568",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ivosidenib"
                    },
                    {
                        "drugbank-id": "DB01224",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Quetiapine"
                    },
                    {
                        "drugbank-id": "DB11718",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Encorafenib"
                    },
                    {
                        "drugbank-id": "DB01084",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Emedastine"
                    },
                    {
                        "drugbank-id": "DB15982",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Berotralstat"
                    },
                    {
                        "drugbank-id": "DB00204",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dofetilide"
                    },
                    {
                        "drugbank-id": "DB00215",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Citalopram"
                    },
                    {
                        "drugbank-id": "DB00261",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Anagrelide"
                    },
                    {
                        "drugbank-id": "DB00280",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Disopyramide"
                    },
                    {
                        "drugbank-id": "DB00283",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Clemastine"
                    },
                    {
                        "drugbank-id": "DB00308",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ibutilide"
                    },
                    {
                        "drugbank-id": "DB00313",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Valproic acid"
                    },
                    {
                        "drugbank-id": "DB00342",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Terfenadine"
                    },
                    {
                        "drugbank-id": "DB00365",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Grepafloxacin"
                    },
                    {
                        "drugbank-id": "DB00468",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Quinine"
                    },
                    {
                        "drugbank-id": "DB00489",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sotalol"
                    },
                    {
                        "drugbank-id": "DB00530",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Erlotinib"
                    },
                    {
                        "drugbank-id": "DB00539",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Toremifene"
                    },
                    {
                        "drugbank-id": "DB00604",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Cisapride"
                    },
                    {
                        "drugbank-id": "DB00637",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Astemizole"
                    },
                    {
                        "drugbank-id": "DB00679",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Thioridazine"
                    },
                    {
                        "drugbank-id": "DB00685",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Trovafloxacin"
                    },
                    {
                        "drugbank-id": "DB00834",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mifepristone"
                    },
                    {
                        "drugbank-id": "DB00875",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Flupentixol"
                    },
                    {
                        "drugbank-id": "DB00907",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Cocaine"
                    },
                    {
                        "drugbank-id": "DB00908",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Quinidine"
                    },
                    {
                        "drugbank-id": "DB01035",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Procainamide"
                    },
                    {
                        "drugbank-id": "DB01100",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pimozide"
                    },
                    {
                        "drugbank-id": "DB01118",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Amiodarone"
                    },
                    {
                        "drugbank-id": "DB01175",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Escitalopram"
                    },
                    {
                        "drugbank-id": "DB01184",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Domperidone"
                    },
                    {
                        "drugbank-id": "DB01208",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sparfloxacin"
                    },
                    {
                        "drugbank-id": "DB01218",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Halofantrine"
                    },
                    {
                        "drugbank-id": "DB01244",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Bepridil"
                    },
                    {
                        "drugbank-id": "DB01267",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Paliperidone"
                    },
                    {
                        "drugbank-id": "DB01356",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lithium cation"
                    },
                    {
                        "drugbank-id": "DB01405",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Temafloxacin"
                    },
                    {
                        "drugbank-id": "DB01624",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Zuclopenthixol"
                    },
                    {
                        "drugbank-id": "DB04844",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Tetrabenazine"
                    },
                    {
                        "drugbank-id": "DB04855",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dronedarone"
                    },
                    {
                        "drugbank-id": "DB04946",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Iloperidone"
                    },
                    {
                        "drugbank-id": "DB05294",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Vandetanib"
                    },
                    {
                        "drugbank-id": "DB06176",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Romidepsin"
                    },
                    {
                        "drugbank-id": "DB06216",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Asenapine"
                    },
                    {
                        "drugbank-id": "DB06697",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Artemether"
                    },
                    {
                        "drugbank-id": "DB06708",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lumefantrine"
                    },
                    {
                        "drugbank-id": "DB09039",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Eliglustat"
                    },
                    {
                        "drugbank-id": "DB09083",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ivabradine"
                    },
                    {
                        "drugbank-id": "DB11730",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ribociclib"
                    },
                    {
                        "drugbank-id": "DB11978",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Glasdegib"
                    },
                    {
                        "drugbank-id": "DB12161",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Deutetrabenazine"
                    },
                    {
                        "drugbank-id": "DB13074",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Macimorelin"
                    },
                    {
                        "drugbank-id": "DB13725",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Terodiline"
                    },
                    {
                        "drugbank-id": "DB04914",
                        "description": "The therapeutic efficacy of G17DT can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05144",
                        "description": "The therapeutic efficacy of PEV3A can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05325",
                        "description": "The therapeutic efficacy of INGN 225 can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05374",
                        "description": "The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05440",
                        "description": "The therapeutic efficacy of SRP 299 can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05942",
                        "description": "The therapeutic efficacy of GI 5005 can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06400",
                        "description": "The therapeutic efficacy of Vitespen can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06584",
                        "description": "The therapeutic efficacy of TG4010 can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09057",
                        "description": "The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10062",
                        "description": "The therapeutic efficacy of Rabies virus inactivated antigen B can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10076",
                        "description": "The therapeutic efficacy of Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10276",
                        "description": "The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10283",
                        "description": "The therapeutic efficacy of Rabies virus inactivated antigen A can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10342",
                        "description": "The therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10583",
                        "description": "The therapeutic efficacy of Clostridium tetani toxoid antigen formaldehyde inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10584",
                        "description": "The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen formaldehyde inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10600",
                        "description": "The therapeutic efficacy of Influenza A virus A California 7 2009 X 181 H1N1 antigen propiolactone inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10769",
                        "description": "The therapeutic efficacy of Japanese encephalitis virus strain sa 14 14 2 antigen formaldehyde inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10794",
                        "description": "The therapeutic efficacy of Influenza B virus B Brisbane 60 2008 antigen formaldehyde inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10803",
                        "description": "The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10989",
                        "description": "The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10990",
                        "description": "The therapeutic efficacy of Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11038",
                        "description": "The therapeutic efficacy of Influenza A virus A Brisbane 59 2007 H1N1 hemagglutinin antigen propiolactone inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11040",
                        "description": "The therapeutic efficacy of Influenza B virus B Brisbane 60 2008 hemagglutinin antigen propiolactone inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11041",
                        "description": "The therapeutic efficacy of Influenza A virus A California 7 2009 X 181 H1N1 hemagglutinin antigen propiolactone inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11044",
                        "description": "The therapeutic efficacy of Influenza B virus B Brisbane 60 2008 antigen propiolactone inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11603",
                        "description": "The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11627",
                        "description": "The therapeutic efficacy of Hepatitis B Vaccine Recombinant can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12568",
                        "description": "The therapeutic efficacy of Tecemotide can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14022",
                        "description": "The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14384",
                        "description": "The therapeutic efficacy of Influenza A virus A Victoria 210 2009 X 187 H3N2 hemagglutinin antigen formaldehyde inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14385",
                        "description": "The therapeutic efficacy of Influenza B virus B Brisbane 60 2008 hemagglutinin antigen formaldehyde inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14394",
                        "description": "The therapeutic efficacy of Influenza A virus A California 7 2009 H1N1 live attenuated antigen can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14445",
                        "description": "The therapeutic efficacy of Influenza A virus A Victoria 210 2009 X 187 H3N2 antigen formaldehyde inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14449",
                        "description": "The therapeutic efficacy of Influenza A virus A Perth 16 2009 H3N2 live attenuated antigen can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14619",
                        "description": "The therapeutic efficacy of Influenza A virus A Uruguay 716 2007 H3N2 antigen propiolactone inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14620",
                        "description": "The therapeutic efficacy of Influenza A virus A Brisbane 59 2007 H1N1 antigen propiolactone inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14711",
                        "description": "The therapeutic efficacy of Smallpox Vaccinia Vaccine Live can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB15274",
                        "description": "The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB15461",
                        "description": "The therapeutic efficacy of Yersinia pestis 195 p antigen formaldehyde inactivated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13924",
                        "description": "The therapeutic efficacy of Varicella Zoster Vaccine Recombinant can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB15483",
                        "description": "The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB15595",
                        "description": "The therapeutic efficacy of Ebola Zaire vaccine live attenuated can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB15654",
                        "description": "The therapeutic efficacy of Moderna COVID 19 Vaccine can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00054",
                        "description": "The risk or severity of bleeding can be increased when Abciximab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00063",
                        "description": "The risk or severity of bleeding can be increased when Eptifibatide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00208",
                        "description": "The risk or severity of bleeding can be increased when Ticlopidine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00758",
                        "description": "The risk or severity of bleeding can be increased when Clopidogrel is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00775",
                        "description": "The risk or severity of bleeding can be increased when Tirofiban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00806",
                        "description": "The risk or severity of bleeding can be increased when Pentoxifylline is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00945",
                        "description": "The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00975",
                        "description": "The risk or severity of bleeding can be increased when Dipyridamole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01088",
                        "description": "The risk or severity of bleeding can be increased when Iloprost is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01138",
                        "description": "The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01207",
                        "description": "The risk or severity of bleeding can be increased when Ridogrel is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01240",
                        "description": "The risk or severity of bleeding can be increased when Epoprostenol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB02709",
                        "description": "The risk or severity of bleeding can be increased when Resveratrol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04743",
                        "description": "The risk or severity of bleeding can be increased when Nimesulide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04905",
                        "description": "The risk or severity of bleeding can be increased when Tesmilifene is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04932",
                        "description": "The risk or severity of bleeding can be increased when Defibrotide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05229",
                        "description": "The risk or severity of bleeding can be increased when Beraprost is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05266",
                        "description": "The risk or severity of bleeding can be increased when Ibudilast is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05767",
                        "description": "The risk or severity of bleeding can be increased when Andrographolide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06081",
                        "description": "The risk or severity of bleeding can be increased when Caplacizumab is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06209",
                        "description": "The risk or severity of bleeding can be increased when Prasugrel is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06441",
                        "description": "The risk or severity of bleeding can be increased when Cangrelor is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB07615",
                        "description": "The risk or severity of bleeding can be increased when Tranilast is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08814",
                        "description": "The risk or severity of bleeding can be increased when Triflusal is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08816",
                        "description": "The risk or severity of bleeding can be increased when Ticagrelor is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08887",
                        "description": "The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09030",
                        "description": "The risk or severity of bleeding can be increased when Vorapaxar is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09283",
                        "description": "The risk or severity of bleeding can be increased when Trapidil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12092",
                        "description": "The risk or severity of bleeding can be increased when Naftopidil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12163",
                        "description": "The risk or severity of bleeding can be increased when Sarpogrelate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12321",
                        "description": "The risk or severity of bleeding can be increased when Ifetroban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12445",
                        "description": "The risk or severity of bleeding can be increased when Nitroaspirin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12465",
                        "description": "The risk or severity of bleeding can be increased when Ketanserin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12545",
                        "description": "The risk or severity of bleeding can be increased when Indobufen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12749",
                        "description": "The risk or severity of bleeding can be increased when Butylphthalide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12771",
                        "description": "The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13036",
                        "description": "The risk or severity of bleeding can be increased when Ramatroban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13327",
                        "description": "The risk or severity of bleeding can be increased when Picotamide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13367",
                        "description": "The risk or severity of bleeding can be increased when Cloricromen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13400",
                        "description": "The risk or severity of bleeding can be increased when Linsidomine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13510",
                        "description": "The risk or severity of bleeding can be increased when Buflomedil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13929",
                        "description": "The risk or severity of bleeding can be increased when Relcovaptan is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08881",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Vemurafenib"
                    },
                    {
                        "drugbank-id": "DB11988",
                        "description": "Ocrelizumab may increase the immunosuppressive activities of Eribulin"
                    },
                    {
                        "drugbank-id": "DB11637",
                        "description": "Eribulin may increase the QTc prolonging activities of Delamanid"
                    },
                    {
                        "drugbank-id": "DB13200",
                        "description": "Eribulin may increase the myelosuppressive activities of Lipegfilgrastim"
                    },
                    {
                        "drugbank-id": "DB10317",
                        "description": "The risk or severity of infection can be increased when Rubella virus vaccine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10318",
                        "description": "The risk or severity of infection can be increased when Varicella Zoster Vaccine Live attenuated is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10343",
                        "description": "The risk or severity of infection can be increased when Bacillus calmette guerin substrain tice live antigen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10804",
                        "description": "The risk or severity of infection can be increased when Bacillus calmette guerin substrain connaught live antigen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB10805",
                        "description": "The risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11003",
                        "description": "The risk or severity of infection can be increased when Anthrax vaccine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11050",
                        "description": "The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12386",
                        "description": "The risk or severity of infection can be increased when Bacillus calmette guerin substrain danish 1331 live antigen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12768",
                        "description": "The risk or severity of infection can be increased when BCG vaccine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14409",
                        "description": "The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl 68578 antigen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14443",
                        "description": "The risk or severity of infection can be increased when Vibrio cholerae CVD 103 HgR strain live antigen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14685",
                        "description": "The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00039",
                        "description": "The therapeutic efficacy of Palifermin can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00104",
                        "description": "The risk or severity of QTc prolongation can be increased when Octreotide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00107",
                        "description": "The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00187",
                        "description": "The risk or severity of QTc prolongation can be increased when Esmolol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00196",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00220",
                        "description": "The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00230",
                        "description": "The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00245",
                        "description": "The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00270",
                        "description": "The risk or severity of QTc prolongation can be increased when Isradipine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00285",
                        "description": "The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00289",
                        "description": "The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00334",
                        "description": "The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00341",
                        "description": "The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00344",
                        "description": "The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00346",
                        "description": "The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00347",
                        "description": "The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00354",
                        "description": "The risk or severity of QTc prolongation can be increased when Buclizine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00358",
                        "description": "The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00366",
                        "description": "The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00370",
                        "description": "The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00373",
                        "description": "The risk or severity of QTc prolongation can be increased when Timolol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00374",
                        "description": "The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00390",
                        "description": "The risk or severity of QTc prolongation can be increased when Digoxin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00405",
                        "description": "The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00424",
                        "description": "The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00427",
                        "description": "The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00434",
                        "description": "The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00467",
                        "description": "The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00487",
                        "description": "The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00503",
                        "description": "The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00529",
                        "description": "The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00540",
                        "description": "The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00543",
                        "description": "The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00555",
                        "description": "The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00582",
                        "description": "The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00593",
                        "description": "The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00613",
                        "description": "The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00622",
                        "description": "The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00674",
                        "description": "The risk or severity of QTc prolongation can be increased when Galantamine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00675",
                        "description": "The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00678",
                        "description": "The risk or severity of QTc prolongation can be increased when Losartan is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00680",
                        "description": "The risk or severity of QTc prolongation can be increased when Moricizine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00691",
                        "description": "The risk or severity of QTc prolongation can be increased when Moexipril is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00697",
                        "description": "The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00710",
                        "description": "The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00714",
                        "description": "The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00719",
                        "description": "The risk or severity of QTc prolongation can be increased when Azatadine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00726",
                        "description": "The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00734",
                        "description": "The risk or severity of QTc prolongation can be increased when Risperidone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00753",
                        "description": "The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00808",
                        "description": "The risk or severity of QTc prolongation can be increased when Indapamide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00817",
                        "description": "The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00818",
                        "description": "The risk or severity of QTc prolongation can be increased when Propofol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00822",
                        "description": "The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00825",
                        "description": "The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00835",
                        "description": "The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00862",
                        "description": "The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00871",
                        "description": "The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00909",
                        "description": "The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00915",
                        "description": "The risk or severity of QTc prolongation can be increased when Amantadine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00916",
                        "description": "The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00920",
                        "description": "The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00927",
                        "description": "The risk or severity of QTc prolongation can be increased when Famotidine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00934",
                        "description": "The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00938",
                        "description": "The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00949",
                        "description": "The risk or severity of QTc prolongation can be increased when Felbamate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00983",
                        "description": "The risk or severity of QTc prolongation can be increased when Formoterol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01001",
                        "description": "The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01023",
                        "description": "The risk or severity of QTc prolongation can be increased when Felodipine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01026",
                        "description": "The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01036",
                        "description": "The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01044",
                        "description": "The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01054",
                        "description": "The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01059",
                        "description": "The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01069",
                        "description": "The risk or severity of QTc prolongation can be increased when Promethazine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01071",
                        "description": "The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01072",
                        "description": "The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01074",
                        "description": "The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01075",
                        "description": "The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01106",
                        "description": "The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01142",
                        "description": "The risk or severity of QTc prolongation can be increased when Doxepin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01151",
                        "description": "The risk or severity of QTc prolongation can be increased when Desipramine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01158",
                        "description": "The risk or severity of QTc prolongation can be increased when Bretylium is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01166",
                        "description": "The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01167",
                        "description": "The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01173",
                        "description": "The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01176",
                        "description": "The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01189",
                        "description": "The risk or severity of QTc prolongation can be increased when Desflurane is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01228",
                        "description": "The risk or severity of QTc prolongation can be increased when Encainide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01233",
                        "description": "The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01236",
                        "description": "The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01238",
                        "description": "The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01239",
                        "description": "The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01246",
                        "description": "The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01259",
                        "description": "The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01263",
                        "description": "The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01274",
                        "description": "The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01396",
                        "description": "The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01403",
                        "description": "The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01426",
                        "description": "The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01591",
                        "description": "The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01620",
                        "description": "The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01623",
                        "description": "The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04576",
                        "description": "The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04695",
                        "description": "The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04846",
                        "description": "The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04953",
                        "description": "The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05039",
                        "description": "The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05246",
                        "description": "The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05465",
                        "description": "The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06217",
                        "description": "The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06282",
                        "description": "The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06288",
                        "description": "The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06468",
                        "description": "The risk or severity of QTc prolongation can be increased when Cariporide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06663",
                        "description": "The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06691",
                        "description": "The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06699",
                        "description": "The risk or severity of QTc prolongation can be increased when Degarelix is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06719",
                        "description": "The risk or severity of QTc prolongation can be increased when Buserelin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06788",
                        "description": "The risk or severity of QTc prolongation can be increased when Histrelin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06825",
                        "description": "The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB07780",
                        "description": "The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB07841",
                        "description": "The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08808",
                        "description": "The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08815",
                        "description": "The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08864",
                        "description": "The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08893",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Mirabegron"
                    },
                    {
                        "drugbank-id": "DB08912",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dabrafenib"
                    },
                    {
                        "drugbank-id": "DB08936",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Chlorcyclizine"
                    },
                    {
                        "drugbank-id": "DB08972",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Flumequine"
                    },
                    {
                        "drugbank-id": "DB09080",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Olodaterol"
                    },
                    {
                        "drugbank-id": "DB09089",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Trimebutine"
                    },
                    {
                        "drugbank-id": "DB09090",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pinaverium"
                    },
                    {
                        "drugbank-id": "DB09167",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dosulepin"
                    },
                    {
                        "drugbank-id": "DB09229",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Aranidipine"
                    },
                    {
                        "drugbank-id": "DB09235",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Efonidipine"
                    },
                    {
                        "drugbank-id": "DB09236",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lacidipine"
                    },
                    {
                        "drugbank-id": "DB09239",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Niguldipine"
                    },
                    {
                        "drugbank-id": "DB09488",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Acrivastine"
                    },
                    {
                        "drugbank-id": "DB11390",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Coumaphos"
                    },
                    {
                        "drugbank-id": "DB11397",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Dichlorvos"
                    },
                    {
                        "drugbank-id": "DB11408",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Famphur"
                    },
                    {
                        "drugbank-id": "DB11412",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Fenthion"
                    },
                    {
                        "drugbank-id": "DB11443",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Orbifloxacin"
                    },
                    {
                        "drugbank-id": "DB11448",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Phosmet"
                    },
                    {
                        "drugbank-id": "DB11491",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sarafloxacin"
                    },
                    {
                        "drugbank-id": "DB11511",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Difloxacin"
                    },
                    {
                        "drugbank-id": "DB11591",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Bilastine"
                    },
                    {
                        "drugbank-id": "DB11614",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Rupatadine"
                    },
                    {
                        "drugbank-id": "DB11742",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ebastine"
                    },
                    {
                        "drugbank-id": "DB11770",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Talinolol"
                    },
                    {
                        "drugbank-id": "DB11774",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pazufloxacin"
                    },
                    {
                        "drugbank-id": "DB11785",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Anisodamine"
                    },
                    {
                        "drugbank-id": "DB11891",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with CUDC 907"
                    },
                    {
                        "drugbank-id": "DB11892",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Prulifloxacin"
                    },
                    {
                        "drugbank-id": "DB11943",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Delafloxacin"
                    },
                    {
                        "drugbank-id": "DB12093",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Tetrahydropalmatine"
                    },
                    {
                        "drugbank-id": "DB12231",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Temefos"
                    },
                    {
                        "drugbank-id": "DB12245",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Triclabendazole"
                    },
                    {
                        "drugbank-id": "DB12645",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Givinostat"
                    },
                    {
                        "drugbank-id": "DB12712",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pilsicainide"
                    },
                    {
                        "drugbank-id": "DB12766",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Cicletanine"
                    },
                    {
                        "drugbank-id": "DB12923",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Gallopamil"
                    },
                    {
                        "drugbank-id": "DB13358",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Cibenzoline"
                    },
                    {
                        "drugbank-id": "DB13488",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Bencyclane"
                    },
                    {
                        "drugbank-id": "DB13555",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Prajmaline"
                    },
                    {
                        "drugbank-id": "DB13627",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Oxolinic acid"
                    },
                    {
                        "drugbank-id": "DB13651",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lorajmine"
                    },
                    {
                        "drugbank-id": "DB13691",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Acetyldigoxin"
                    },
                    {
                        "drugbank-id": "DB13744",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Piromidic acid"
                    },
                    {
                        "drugbank-id": "DB13766",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Lidoflazine"
                    },
                    {
                        "drugbank-id": "DB13772",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Rufloxacin"
                    },
                    {
                        "drugbank-id": "DB13823",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Pipemidic acid"
                    },
                    {
                        "drugbank-id": "DB14185",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Aripiprazole lauroxil"
                    },
                    {
                        "drugbank-id": "DB14713",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Inotersen"
                    },
                    {
                        "drugbank-id": "DB00999",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00845",
                        "description": "The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11796",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Fostemsavir"
                    },
                    {
                        "drugbank-id": "DB00751",
                        "description": "The risk or severity of QTc prolongation can be increased when Epinastine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11853",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Relugolix"
                    },
                    {
                        "drugbank-id": "DB00001",
                        "description": "The risk or severity of bleeding can be increased when Lepirudin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00006",
                        "description": "The risk or severity of bleeding can be increased when Bivalirudin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00009",
                        "description": "The risk or severity of bleeding can be increased when Alteplase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00013",
                        "description": "The risk or severity of bleeding can be increased when Urokinase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00015",
                        "description": "The risk or severity of bleeding can be increased when Reteplase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00029",
                        "description": "The risk or severity of bleeding can be increased when Anistreplase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00031",
                        "description": "The risk or severity of bleeding can be increased when Tenecteplase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00055",
                        "description": "The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00086",
                        "description": "The risk or severity of bleeding can be increased when Streptokinase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00266",
                        "description": "The risk or severity of bleeding can be increased when Dicoumarol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00278",
                        "description": "The risk or severity of bleeding can be increased when Argatroban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00407",
                        "description": "The risk or severity of bleeding can be increased when Ardeparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00498",
                        "description": "The risk or severity of bleeding can be increased when Phenindione is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00569",
                        "description": "The risk or severity of bleeding can be increased when Fondaparinux is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00682",
                        "description": "The risk or severity of bleeding can be increased when Warfarin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00686",
                        "description": "The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00946",
                        "description": "The risk or severity of bleeding can be increased when Phenprocoumon is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01109",
                        "description": "The risk or severity of bleeding can be increased when Heparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01225",
                        "description": "The risk or severity of bleeding can be increased when Enoxaparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01418",
                        "description": "The risk or severity of bleeding can be increased when Acenocoumarol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB03410",
                        "description": "The risk or severity of bleeding can be increased when 4 hydroxycoumarin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04665",
                        "description": "The risk or severity of bleeding can be increased when Coumarin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04898",
                        "description": "The risk or severity of bleeding can be increased when Ximelagatran is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB04925",
                        "description": "The risk or severity of bleeding can be increased when Desmoteplase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05099",
                        "description": "The risk or severity of bleeding can be increased when Ancrod is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB05254",
                        "description": "The risk or severity of bleeding can be increased when Fibrinolysin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06228",
                        "description": "The risk or severity of bleeding can be increased when Rivaroxaban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06271",
                        "description": "The risk or severity of bleeding can be increased when Sulodexide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06294",
                        "description": "The risk or severity of bleeding can be increased when Semuloparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06406",
                        "description": "The risk or severity of bleeding can be increased when Idraparinux is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06543",
                        "description": "The risk or severity of bleeding can be increased when Astaxanthin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06605",
                        "description": "The risk or severity of bleeding can be increased when Apixaban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06635",
                        "description": "The risk or severity of bleeding can be increased when Otamixaban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06679",
                        "description": "The risk or severity of bleeding can be increased when Amediplase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06695",
                        "description": "The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06754",
                        "description": "The risk or severity of bleeding can be increased when Danaparoid is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06779",
                        "description": "The risk or severity of bleeding can be increased when Dalteparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB06822",
                        "description": "The risk or severity of bleeding can be increased when Tinzaparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB07767",
                        "description": "The risk or severity of bleeding can be increased when Ferulic acid is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08496",
                        "description": "The risk or severity of bleeding can be increased when R warfarin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08794",
                        "description": "The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08813",
                        "description": "The risk or severity of bleeding can be increased when Nadroparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB08994",
                        "description": "The risk or severity of bleeding can be increased when Ditazole is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09075",
                        "description": "The risk or severity of bleeding can be increased when Edoxaban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09125",
                        "description": "The risk or severity of bleeding can be increased when Potassium citrate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09154",
                        "description": "The risk or severity of bleeding can be increased when Sodium citrate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09255",
                        "description": "The risk or severity of bleeding can be increased when Dextran is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09258",
                        "description": "The risk or severity of bleeding can be increased when Bemiparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09260",
                        "description": "The risk or severity of bleeding can be increased when Parnaparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11095",
                        "description": "The risk or severity of bleeding can be increased when Desirudin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11154",
                        "description": "The risk or severity of bleeding can be increased when Zinc citrate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11166",
                        "description": "The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11312",
                        "description": "The risk or severity of bleeding can be increased when Protein C is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11598",
                        "description": "The risk or severity of bleeding can be increased when Antithrombin III human is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11984",
                        "description": "The risk or severity of bleeding can be increased when Letaxaban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12289",
                        "description": "The risk or severity of bleeding can be increased when Darexaban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12364",
                        "description": "The risk or severity of bleeding can be increased when Betrixaban is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12598",
                        "description": "The risk or severity of bleeding can be increased when Nafamostat is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12726",
                        "description": "The risk or severity of bleeding can be increased when Monteplase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12831",
                        "description": "The risk or severity of bleeding can be increased when Gabexate is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13136",
                        "description": "The risk or severity of bleeding can be increased when Fluindione is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13149",
                        "description": "The risk or severity of bleeding can be increased when Protein S human is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13199",
                        "description": "The risk or severity of bleeding can be increased when Brinase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13275",
                        "description": "The risk or severity of bleeding can be increased when Clorindione is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13347",
                        "description": "The risk or severity of bleeding can be increased when Diphenadione is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13451",
                        "description": "The risk or severity of bleeding can be increased when Tioclomarol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13616",
                        "description": "The risk or severity of bleeding can be increased when Melagatran is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13646",
                        "description": "The risk or severity of bleeding can be increased when Saruplase is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14055",
                        "description": "The risk or severity of bleeding can be increased when S Warfarin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14094",
                        "description": "The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14598",
                        "description": "The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB14726",
                        "description": "The risk or severity of bleeding can be increased when Dabigatran is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13124",
                        "description": "The risk or severity of bleeding can be increased when Troxerutin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00974",
                        "description": "The risk or severity of bleeding can be increased when Edetic acid is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09259",
                        "description": "The risk or severity of bleeding can be increased when Reviparin is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00232",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Methyclothiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00436",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00562",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00606",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00774",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00880",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01021",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01324",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13430",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Mebutizide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB13532",
                        "description": "The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB09042",
                        "description": "The risk or severity of myelosuppression can be increased when Eribulin is combined with Tedizolid phosphate"
                    },
                    {
                        "drugbank-id": "DB00091",
                        "description": "Eribulin may increase the immunosuppressive activities of Cyclosporine"
                    },
                    {
                        "drugbank-id": "DB00115",
                        "description": "The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00437",
                        "description": "The risk or severity of adverse effects can be increased when Allopurinol is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00656",
                        "description": "The risk or severity of QTc prolongation can be increased when Trazodone is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB11986",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Entrectinib"
                    },
                    {
                        "drugbank-id": "DB11642",
                        "description": "Eribulin may increase the QTc prolonging activities of Pitolisant"
                    },
                    {
                        "drugbank-id": "DB12825",
                        "description": "Lefamulin may increase the QTc prolonging activities of Eribulin"
                    },
                    {
                        "drugbank-id": "DB00557",
                        "description": "The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB00246",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Ziprasidone"
                    },
                    {
                        "drugbank-id": "DB14513",
                        "description": "The serum concentration of Magnesium can be decreased when it is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB01601",
                        "description": "The serum concentration of Eribulin can be increased when it is combined with Lopinavir"
                    },
                    {
                        "drugbank-id": "DB00502",
                        "description": "The risk or severity of QTc prolongation can be increased when Eribulin is combined with Haloperidol"
                    },
                    {
                        "drugbank-id": "DB00472",
                        "description": "The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Eribulin"
                    },
                    {
                        "drugbank-id": "DB12530",
                        "description": "The risk or severity of infection can be increased when Eribulin is combined with Inebilizumab"
                    }
                ]
            }
        },
        "revision_date": "2023-05-14"
    }
}